Citigroup Initiates Coverage On Alpha Tau Medical with Buy Rating, Announces Price Target of $8
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Ashiq Mubarack has initiated coverage on Alpha Tau Medical (NASDAQ:DRTS) with a Buy rating and set a price target of $8 for the company's stock.
December 15, 2023 | 2:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup has initiated coverage on Alpha Tau Medical with a Buy rating and a price target of $8, which could positively influence the stock's performance in the short term.
Analyst coverage, especially from a major financial institution like Citigroup, can significantly impact a stock's performance. A Buy rating coupled with a price target that suggests upside potential is likely to be viewed positively by investors, potentially leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100